**Mississippi Cancer Registry Newsletter**

**SEPT 2020 | Volume 15 Issue 3**

**INSIDE THIS ISSUE:**

<table>
<thead>
<tr>
<th>Educational Corner</th>
<th>Congratulations!</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abstracting Resources</td>
<td>Announcement</td>
</tr>
<tr>
<td>Upcoming Webinars</td>
<td>MCR Staff</td>
</tr>
<tr>
<td>CTR Exam</td>
<td></td>
</tr>
</tbody>
</table>
EDUCATIONAL CORNER

CHANGES, CHANGES, CHANGES......

Upcoming changes for 2021 (for cases diagnosed 01/01/2021 or after):

*Post-therapy Clinical yc Staging:

What is yc staging?
- Staging after neoadjuvant treatment, but before surgery of the primary site

Why is yc stage necessary?
- Shows patient treatment plan initially included surgery
- Treatment plan changed due to “good” or “poor” response
- Shows exact level of response compared to clinical stage

Registrar never assigns more than 2 AJCC stage classifications
- Only ask for yc when yp cannot be assigned
- Provides assessment of response, which is the difference between cTNM and ycTNM

When yc staging must be used
- yc assigned when
  - Treatment plan is neoadjuvant followed by surgery
  - But surgery is canceled
- yc includes:
  - Evaluation by physical exam, imaging, biopsy, and any diagnostic procedures

Examples of yc staging:
- Patient doesn’t respond to neoadjuvant treatment, surgery is canceled
- Patient responds so well, surgery is no longer indicated

(Resource: Update on AJCC 8th Edition TNM Staging Webinar by Donna Gress, RHIT, CTR)
Additional Changes for 2021:

*AJCC to Release Version 9 Cervix Uteri Cancer Staging System:

The new Version 9 content, presented in a streamlined, easy-to-use format, incorporates the 2018 Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) staging classification, as well as the World Health Organization (WHO) 2020 Classification of Tumors histology codes. Physicians, registrars, researchers, and other content users will be able to purchase the electronic format of the updated Cervix Uteri content, including tables, explanatory notes and illustrations starting October 25, 2020. Version 9 becomes effective on January 1, 2021 and replaces the 8th Edition Cervix Uteri cancer site content. All other disease sites in the 8th Edition Cancer Staging Manual remain current for 2021.

*CDC-NPCR Requirement:

Beginning 01/01/2021 all GIST tumors are reportable and will use the behavior code /3.

*ICD-O:

ICD-O Site/Type Validation Update for cases diagnosed 01/01/2021 and after can be found at the following link https://seer.cancer.gov/icd-o-3/errata.sitetype.20200629.pdf

*Solid Tumor Rules:

Melanoma is the only new Solid Tumor Rule chapter that will be released in 2021, release date unknown at this time. Based on the recent WHO 4th Ed Tumors of Skin, we do not expect major changes to the cutaneous melanoma rules.

**FLccSC**

**Fundamental Learning Collaborative for the Cancer Surveillance Community:**

The FLccSC site is up and running. If you have not yet registered you can do so at the link below. The MS FLccSC site will stay updated with current news, webinars and educational opportunities. You do not want to miss out!

mss.fcdrmed.med.miami.edu

For more information contact: Angel Davis, CTR, RHIT: adavis6@umc.edu
ABSTRACTING RESOURCES

AJCC Cancer Staging Manual
Cases with a diagnosis date of 01/01/2018 and forward should be staged using AJCC 8th Edition Cancer Staging Manual. The 3rd printing 2018 Edition is now available.

Please visit https://cancerstaging.org/references-tools/deskreferences/Pages/8EUpdates.aspx# for all 8th Edition updates and corrections. For all other information, visit https://cancerstaging.org/Pages/default.aspx.

Summary Stage 2018
The 2018 version of Summary Stage applies to every site and/or histology combination, including lymphomas and leukemias. Summary Stage uses all information available in the medical record; in other words, it is a combination of the most precise clinical and pathological documentation of the extent of disease. The Summary Stage 2018 manual is available at https://seer.cancer.gov/tools/ssm/.

Site Specific Data Items (SSDI)
Site Specific Data Items (SSDI) are similar to the Site Specific Factors (SSF) collected with Collaborative Stage. These data items are specific to certain site/histology combinations. For example, the SSDI’s for breast will be used to collect information such as estrogen receptor status, progesterone receptor status, Her2 status, Nottingham grade, and additional information related to primary tumors of the breast. The information collected in these data items are specific to breast. The SSDI manual is available at https://apps.naaccr.org/ssdi/list/.

Grade
Beginning with cases diagnosed in 2018 grade information will be collected in three fields; Clinical Grade, Pathological Grade, and Post-Therapy Grade. Within the Grade Manual you will find definitions for the three new grade data items, coding instructions, and the site/histology specific grade tables. The Grade manual is available at https://www.naaccr.org/SSDI/Grade-Manual.pdf?v=1527859766.

SEER Hematopoietic and Lymphoid Neoplasm Database

2018 Solid Tumor Coding Manual
Use the 2018 Solid Tumor coding rules to determine the number of primaries to abstract and the histology to code for cases diagnosed 2018 and forward. The Solid Tumor coding rules replace the 2007 Multiple Primary and Histology( MP/H) Rules. The manual is available at https://seer.cancer.gov/tools/solidtumor/. The change log contains updates made to the FINAL module sections. This does not include changes made to the drafts.

CoC 2018 STORE Manual
Upcoming Webinars

10/1/20 Prostate
Guest Host: Wilson Apollo

11/5/20 Lung
Guest Host: Denise Harrison, Kelli Olsen

For more information contact: Angel Davis, adavis6@umc.edu

Upcoming CTR Exam

The October 16 - November 6, 2020 testing window is expanded to start on October 12 and run through November 14, 2020.

Application Deadline: October 11

For more information visit: www.ncra-usa.org/CTR
NEW CERTIFIED TUMOR REGISTRARS

SARAH PATRICK at University of MS Medical Center

BRANDY SHEFFIELD at North MS Medical Center

ANDERSON REGIONAL CANCER CENTER

Kathy Swartzfager will be retiring by the end of the year from the Registry after 20+ years. Her job is actually posted on the hospital web site, andersonregional.org., and at Indeed.com. Erika Holloway left the Registry in mid June to work remotely from home.
Director UMMC & MCR:  
Deirdre Rogers, dbrogers@umc.edu

MCR Manager:  
La’Tawnya Roby, ldroby@umc.edu

Clinical Systems-Application coordinator/Analyst-Intermediate  
Tresheena Boyd, tboyd@umc.edu

Data Quality Analyst– Trainer  
Angel Davis, adavis6@umc.edu

Data Quality Analyst– Auditor  
April Huggins, ahuggins@umc.edu

Electronic Data Source Coordinator:  
Lisa Hamel, lhamel@umc.edu

Cancer Registrars:  
Stacy Major, semajor@umc.edu  
Stephanie N. Engelman, nengelman@umc.edu  
LaToya Boga, lbogan@umc.edu  
Cameron Proctor, cproctor@umc.edu

Administrative Assistant:  
Ophelia Spencer, ospencer@umc.edu